These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 11751969)

  • 21. Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules.
    Fridkis-Hareli M; Neveu JM; Robinson RA; Lane WS; Gauthier L; Wucherpfennig KW; Sela M; Strominger JL
    J Immunol; 1999 Apr; 162(8):4697-704. PubMed ID: 10202010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints.
    Latham KA; Whittington KB; Zhou R; Qian Z; Rosloniec EF
    J Immunol; 2005 Apr; 174(7):3978-85. PubMed ID: 15778354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding.
    Busch R; Hill CM; Hayball JD; Lamb JR; Rothbard JB
    J Immunol; 1991 Aug; 147(4):1292-8. PubMed ID: 1869824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breaking T cell tolerance against self type II collagen in HLA-DR4-transgenic mice and development of autoimmune arthritis.
    Batsalova T; Dzhambazov B; Merky P; Bäcklund A; Bäcklund J
    Arthritis Rheum; 2010 Jul; 62(7):1911-20. PubMed ID: 20309862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of HLA-DR1 with the allergic response to the major mugwort pollen allergen: molecular background.
    Knapp B; Fischer G; Van Hemelen D; Fae I; Maillere B; Ebner C; Schreiner W; Bohle B; Jahn-Schmid B
    BMC Immunol; 2012 Aug; 13():43. PubMed ID: 22871092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome.
    Matsushita S; Takahashi K; Motoki M; Komoriya K; Ikagawa S; Nishimura Y
    J Exp Med; 1994 Sep; 180(3):873-83. PubMed ID: 8064238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rheumatoid arthritis-associated allele HLA-DR10 (DRB1*1001) shares part of its repertoire with HLA-DR1 (DRB1*0101) and HLA-DR4 (DRB*0401).
    Alvarez I; Collado J; Daura X; Colomé N; Rodríguez-García M; Gallart T; Canals F; Jaraquemada D
    Arthritis Rheum; 2008 Jun; 58(6):1630-9. PubMed ID: 18512783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model.
    von Delwig A; Altmann DM; Isaacs JD; Harding CV; Holmdahl R; McKie N; Robinson JH
    Arthritis Rheum; 2006 Feb; 54(2):482-91. PubMed ID: 16447222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analog peptide that suppresses collagen-induced arthritis.
    Myers LK; Sakurai Y; Rosloniec EF; Stuart JM; Kang AH
    Am J Med Sci; 2004 Apr; 327(4):212-6. PubMed ID: 15084917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human collagen II peptide 256-271 preferentially binds to HLA-DR molecules associated with susceptibility to rheumatoid arthritis.
    Diab BY; Lambert NC; L'Faqihi FE; Loubet-Lescoulié P; de Préval C; Coppin H
    Immunogenetics; 1999 Jan; 49(1):36-44. PubMed ID: 9811967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crystallization of HLA-DR4 fused to an immunodominant collagen II peptide implicated in rheumatoid arthritis.
    Hurlbert JC; Izard T
    Acta Crystallogr D Biol Crystallogr; 2002 Oct; 58(Pt 10 Pt 1):1749-51. PubMed ID: 12351899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice.
    von Delwig A; Altmann DM; Charlton FG; McKie N; Isaacs JD; Holmdahl R; Robinson JH
    Ann Rheum Dis; 2007 May; 66(5):599-604. PubMed ID: 17114189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of HLA-DR4 (0401) on the immune response to type II collagen and the development of collagen induced arthritis in mice.
    Wang D; Hill JA; Cairns E; Bell DA
    J Autoimmun; 2002 Mar; 18(2):95-103. PubMed ID: 11908942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct conformations of a peptide bound to HLA-DR1 or DRB5*0101 suggested by molecular modelling.
    Jurcevic S; Travers PJ; Hills A; Agrewala JN; Moreno C; Ivanyi J
    Int Immunol; 1996 Nov; 8(11):1807-14. PubMed ID: 8943576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effect of polymorphism at HLA-DR1 beta-chain positions 85 and 86 on binding and recognition of DR1-restricted antigenic peptides.
    Newton-Nash DK; Eckels DD
    J Immunol; 1993 Mar; 150(5):1813-21. PubMed ID: 7679697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice.
    von Delwig A; Hilkens CM; Altmann DM; Holmdahl R; Isaacs JD; Harding CV; Robertson H; McKie N; Robinson JH
    Arthritis Res Ther; 2006; 8(4):R93. PubMed ID: 16704744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis.
    Ito K; Bian HJ; Molina M; Han J; Magram J; Saar E; Belunis C; Bolin DR; Arceo R; Campbell R; Falcioni F; Vidović D; Hammer J; Nagy ZA
    J Exp Med; 1996 Jun; 183(6):2635-44. PubMed ID: 8676084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HLA-DR binding analysis of peptides from islet antigens in IDDM.
    Geluk A; van Meijgaarden KE; Schloot NC; Drijfhout JW; Ottenhoff TH; Roep BO
    Diabetes; 1998 Oct; 47(10):1594-601. PubMed ID: 9753297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The N-terminal six residues of peptide core sequences suffice for binding to HLA-DR4 (DRB1*0405) and DR9 (DRB1*0901) molecules.
    Matsushita S; Fujisao S; Nishimura Y
    Immunol Lett; 1997 Jul; 58(2):89-93. PubMed ID: 9271318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients.
    Schuenke KW; Cook RG; Rich RR
    Hum Immunol; 1998 Dec; 59(12):783-93. PubMed ID: 9831134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.